This brand name is authorized in Ecuador
The drug CINAGERON contains a combination of these active pharmaceutical ingredients (APIs):
|
1
Cinnarizine
UNII 3DI2E1X18L - CINNARIZINE
|
|
Cinnarizine has been shown to be a non-competitive antagonist of the smooth muscle contractions caused by various vasoactive agents including histamine. Cinnarizine also acts on vascular smooth muscle by selectively inhibiting the calcium influx into depolarised cells, thereby reducing the availability of free Ca2+ ions for the induction and maintenance of contraction. |
|
2
Dihydroergocristine
UNII DS7CL18UAM - DIHYDROERGOCRISTINE MESYLATE
|
|
|
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| N07CA52 | Cinnarizine, combinations | N Nervous system → N07 Other nervous system drugs → N07C Antivertigo preparations → N07CA Antivertigo preparations |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: EC | Agencia Nacional de Regulación, Control y Vigilancia Sanitaria | Identifier(s): 5.896-3-09-04 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
